Nephrolithiasis: Molecular mechanism of renal stone formation and the critical role played by modulators

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Aggarwal, Kanu Priya ^a   Narula, Shifa ^a   Kakkar, Monica ^b   Tandon, Chanderdeep ^a  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b HIMALAYAN INSTITUTE HOSPITAL TRUST   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; ALPHA DEFENSIN; APATITE; CALCIUM OXALATE; CALCIUM PHOSPHATE; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HERMES ANTIGEN; HISTONE LYSINE METHYLTRANSFERASE; HYALURONIC ACID; LIPID; LITHOSTATHINE; MATRIX PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NUCLEOLIN; OSTEOPONTIN; PROTHROMBIN; STRUVITE; TAMM HORSFALL GLYCOPROTEIN; ULINASTATIN; URIC ACID; WNT2 PROTEIN; CITRIC ACID; MAGNESIUM; SODIUM;

APOPTOSIS; ARTICLE; CALCIUM OXALATE STONE; CELL DAMAGE; CELL INTERACTION; CRYSTAL; CRYSTALLIZATION; HEALTH CARE; HUMAN; KIDNEY TUBULE CELL; KIDNEY TUBULE DAMAGE; MOLECULAR MECHANICS; NEPHROLITHIASIS; NONHUMAN; OXIDATIVE STRESS; STONE FORMATION; UPREGULATION; URIC ACID STONE; URINE VOLUME; UROLITHIASIS; CHEMISTRY; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; REVIEW; URINE;

CALCIUM OXALATE; CITRATES; CRYSTALLIZATION; FEMALE; HUMANS; MAGNESIUM; MALE; NEPHROLITHIASIS; SODIUM;

EID: 84884898961     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/292953     Document Type: Article

References (229)

1. Eknoyan G., History of urolithiasis. Clinical Reviews in Bone and Mineral Metabolism 2004 2 3 177 185 2-s2.0-26244467264 10.1385/BMM:2:3:177 (Pubitemid 41410970)
2. López M., Hoppe B., History, epidemiology and regional diversities of urolithiasis. Pediatric Nephrology 2010 25 1 49 59 2-s2.0-76749120622 10.1007/s00467-008-0960-5
3. Wilkinson H., Clinical investigation and management of patients with renal stones. Annals of Clinical Biochemistry 2001 38 3 180 187 2-s2.0-0035001728 10.1258/0004563011900623 (Pubitemid 32429999)
4. Bihl G., Meyers A., Recurrent renal stone disease-advances in pathogenesis and clinical management. The Lancet 2001 358 9282 651 656 2-s2.0-0035949090 10.1016/S0140-6736(01)05782-8 (Pubitemid 32786837)
5. Reynolds T. M., Chemical pathology clinical investigation and management of nephrolithiasis. Journal of Clinical Pathology 2005 58 2 134 140 2-s2.0-13244298513 10.1136/jcp.2004.019588 (Pubitemid 40193796)
6. Aggarwal S., Tandon C. D., Forouzandeh M., Singla S. K., Kiran R., Jethi R. K., Role of biomolecules from human renal stone matrix on COM crystal growth. Molecular and Cellular Biochemistry 2000 210 1-2 109 119 2-s2.0-0033898884 (Pubitemid 30639062)
7. Gill W. B., Jones K. W., Ruggiero K. J., Protective effects of heparin and other sulfated glycosaminoglycans on crystal adhesion to injured urothelium. The Journal of Urology 1982 127 1 152 154 2-s2.0-0020047332 (Pubitemid 12172238)
8. Bigelow M. W., Wiessner J. H., Kleinman J. G., Mandel N. S., Calcium oxalate-crystal membrane interactions: dependence on membrane lipid composition. The Journal of Urology 1996 155 3 1094 1098 2-s2.0-0030054306 10.1016/S0022-5347(01)66398-5 (Pubitemid 26052722)
9. Khan S. R., Kok D. J., Modulators of urinary stone formation. Frontiers in Bioscience 2004 9 1450 1482 2-s2.0-2442698061 (Pubitemid 39060855)
10. Doyle I. R., Ryall R. L., Marshall V. R., Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon. Clinical Chemistry 1991 37 9 1589 1594 2-s2.0-0026095244 (Pubitemid 21905223)
11. Morse R. M., Resnick M. I., A new approach to the study of urinary macromolecules as a participant in calcium oxalate crystallization. The Journal of Urology 1988 139 4 869 873 2-s2.0-0023926692
12. King J. S. Jr., Boyce W. H., Immunological studies on serum and urinary proteins in urolith matrix in man. Annals of the New York Academy of Sciences 1963 104 5791 2-s2.0-75449145978
13. Robertson W. G., Peacock M., Nordin B. E. C., Activity products in stone-forming and non-stone-forming urine. Clinical Science 1968 34 3 579 594 2-s2.0-0014290818
14. Boyce W. H., Organic matrix of human urinary concretions. The American Journal of Medicine 1968 45 5 673 683 2-s2.0-0014360415
15. Khan S. R., Shevock P. N., Hackett R. L., Presence of lipids in urinary stones: results of preliminary studies. Calcified Tissue International 1988 42 2 91 96 2-s2.0-0023856960 (Pubitemid 18050534)
16. Sugimoto T., Funae Y., Rubben H., Nishio S., Hautmann R., Lutzeyer W., Resolution of proteins in the kidney stone matrix using high-performance liquid chromatography. European Urology 1985 11 5 334 340 2-s2.0-0022355393 (Pubitemid 16196188)
17. Vermeulen C. W., Lyon E. S., Mechanisms of genesis and growth of calculi. The American Journal of Medicine 1956 45 5 684 691 2-s2.0-0014360189
18. Finlayson B., Vermeulen C. W., Stewart E. J., Stone matrix and mucoprotein from urine. The Journal of Urology 1961 86 355 363 2-s2.0-0343854494
19. Khan S. R., Hackett R. L., Role of organic matrix in urinary stone formation: an ultrastructural study of crystal matrix interface of calcium oxalate monohydrate stones. The Journal of Urology 1993 15 1 239 245 2-s2.0-0027315837 (Pubitemid 23176021)
20. Doyle I. R., Marshall V. R., Dawson C. J., Ryall R. L., Calcium oxalate crystal matrix extract: the most potent macromolecular inhibitor of crystal growth and aggregation yet tested in undiluted human urine in vitro. Urological Research 1995 23 1 53 62 2-s2.0-0028958001 10.1007/BF00298852
21. Drach G. W., Thorson S., Randolph A., Effects of urinary organic macromelecules on crystallization of calcium oxalate: enhancement of nucleation. The Journal of Urology 1980 123 4 519 523 2-s2.0-0018880006 (Pubitemid 10103840)
22. Ryall R. L., Harnett R. M., Hibberd C. M., Edyvane K. A., Marshall V. R., Effects of chondroitin sulphate, human serum albumin and Tamm-Horsfall mucoprotein on calcium oxalate crystallization in undiluted human urine. Urological Research 1991 19 3 181 188 2-s2.0-0025762267
23. Resnick M. I., Sorrell M. E., Bailey J. A., Boyce W. H., Inhibitory effects of urinary calcium-binding substances on calcium oxalate crystallization. The Journal of Urology 1982 127 3 568 571 2-s2.0-0020069476 (Pubitemid 12147657)
24. Grover P. K., Ryall R. L., Marshall V. R., Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine? Clinica Chimica Acta 1990 190 3 223 238 2-s2.0-0024992739 10.1016/0009-8981(90)90176-S (Pubitemid 20298563)
25. Campbell A. A., Ebrahimpour A., Perez L., Smesko S. A., Nancollas G. H., The dual role of polyelectrolytes and proteins as mineralization promoters and inhibitors of calcium oxalate monohydrate. Calcified Tissue International 1989 45 2 122 128 2-s2.0-0024376097 (Pubitemid 19192654)
26. Utsunomiya M., Koide T., Yoshioka T., Yamaguchi S., Okyama A., Influence of ionic strength on crystal adsorption and inhibitory activity of macromolecules. British Journal of Urology 1993 71 5 516 522 2-s2.0-0027162946 (Pubitemid 23172044)
27. Carvahlo M., Nakagawa Y., Urinary supersaturation and recurrence in nephrolithiasis. International Brazilian Journal of Urology 1999 25 475 479
28. Kok D. J., Papapoulos S. E., Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis. Bone and Mineral 1993 20 1 1 15 2-s2.0-0027447506 (Pubitemid 23069203)
29. Finlayson B., Reid S., The expectation of free and fixed particles in urinary stone disease. Investigative Urology 1978 15 6 442 448 2-s2.0-0017809103 (Pubitemid 8347910)
30. Boskey A. L., Current concepts of the physiology and biochemistry of calcification. Clinical Orthopaedics and Related Research 1981 157 225 257 2-s2.0-0019413769 (Pubitemid 11072171)
31. Smith L. H., Solutions and solute. Endocrinology and Metabolism Clinics of North America 1990 19 4 767 772 2-s2.0-0025654884
32. Fasano J. M., Khan S. R., Intratubular crystallization of calcium oxalate in the presence of membrane vesicles. Kidney International 2001 59 1 169 178 2-s2.0-0035173432 10.1046/j.1523-1755.2001.00477.x (Pubitemid 32055225)
33. Khan S. R., Shevock P. N., Hackett R. L., Membrane-associated crystallization of calcium oxalate. Calcified Tissue International 1990 46 2 116 120 2-s2.0-0025062271
34. Finlayson B., Khan S. R., Hackett R. L., Mechanisms of stone formation-an overview. Scanning Electron Microscopy 1984 3 1419 1425 2-s2.0-0021316979 (Pubitemid 14014857)
35. Honda M., Yoshioka T., Yamaguchi S., Yoshimura K., Miyake O., Utsunomiya M., Koide T., Okuyama A., Characterization of protein components of human urinary crystal surface binding substance. Urological Research 1997 25 5 355 360 2-s2.0-0030733045 10.1007/BF01294665 (Pubitemid 27461609)
36. Kok D. J., Khan S. R., Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney International 1994 46 3 847 854 2-s2.0-0028048204 (Pubitemid 24272044)
37. Hess B., Zipperle L., Jaeger P., Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. American Journal of Physiology 1993 265 6, part 2 F784 F791 2-s2.0-0027718081 (Pubitemid 24027585)
38. Khan S. R., Byer K. J., Thamilselvan S., Hackett R. L., Mccormack W. T., Benson N. A., Vaughn K. L., Erdos G. W., Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. Journal of the American Society of Nephrology 1999 10 14 S457 S463 2-s2.0-0032705806 (Pubitemid 29498600)
39. Kohjimoto Y., Ebisuno M., Tamura M., Ohkawa T., Interactions between calcium oxalate monohydrate crystals and Madin-Darby canine kidney cells: endocytosis and cell proliferation. Urological Research 1996 24 4 193 199 2-s2.0-0029814586 (Pubitemid 26265907)
40. Khan S. R., Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urological Research 1995 23 2 71 79 2-s2.0-0029064344 10.1007/BF00307936
41. Lieske J. C., Deganello S., Toback F. G., Cell-crystal interactions and kidney stone formation. Nephron 1999 81 1 8 17 2-s2.0-0032944558 10.1159/000046293 (Pubitemid 29015462)
42. Lieske J. C., Leonard R., Toback F. G., Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. American Journal of Physiology 1995 268 4, part 2 F604 F612 2-s2.0-0028898236
43. Lieske J. C., Spargo B. H., Toback F. G., Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. The Journal of Urology 1992 148 5 1517 1519 2-s2.0-0026545776
44. Lieske J. C., Swift H., Martin T., Patterson B., Toback F. G., Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 6987 6991 2-s2.0-0028308364 10.1073/pnas.91.15.6987 (Pubitemid 24226787)
45. Hess B., Tamm-Horsfall glycoprotein-inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urological Research 1992 20 1 83 86 2-s2.0-0026467489 10.1007/BF00294343
46. Kumar S., Muchmore A., Tamm-Horsfall protein-uromodulin (1950-1990). Kidney International 1990 37 6 1395 1401 2-s2.0-0025353820
47. Tsujihata M., Miyake O., Yoshimura K., Kakimoto K.-I., Takahara S., Okuyama A., Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. The Journal of Urology 2000 164 5 1718 1723 2-s2.0-0033786621
48. Tsujihata M., Yoshimura K., Tsujikawa K., Tei N., Okuyama A., Fibronectin inhibits endocytosis of calcium oxalate crystals by renal tubular cells. International Journal of Urology 2006 13 6 743 746 2-s2.0-33745252819 10.1111/j.1442-2042.2006.01396.x (Pubitemid 43926766)
49. Lieske J. C., Toback F. G., Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. American Journal of Physiology 1993 264 5 F800 F807 2-s2.0-0027241322 (Pubitemid 23149707)
50. Wiessner J. H., Hasegawa A. T., Hung L. Y., Mandel N. S., Oxalate-induced exposure of phosphatidylserine on the surface of renal epithelial cells in culture. Journal of the American Society of Nephrology 1999 10 supplement 14 S441 S445 2-s2.0-0032724371 (Pubitemid 29498597)
51. Khan S. R., Hackett R. L., Hyperoxaluria, enzymuria and nephrolithiasis. Contributions to Nephrology 1993 101 190 193 2-s2.0-0027346147
52. Khan S. R., Finlayson B., Hackett R. L., Histologic study of the early events in oxalate induced intranephronic calculosis. Investigative Urology 1979 17 3 199 203 2-s2.0-0018635381
53. Khan S. R., Finlayson B., Hackett R. L., Experimental calcium oxalate nephrolithiasis in the rat. The American Journal of Pathology 1982 107 1 59 69 2-s2.0-0020053783 (Pubitemid 12153226)
54. Wiessner J. H., Hasegawa A. T., Hung L. Y., Mandel G. S., Mandel N. S., Mechanisms of calcium oxalate crystal attachment to injured renal collecting duct cells. Kidney International 2001 59 2 637 644 2-s2.0-0035131925 10.1046/j.1523-1755.2001.059002637.x (Pubitemid 32157928)
55. Hackett R. L., Shevock P. N., Khan S. R., Madin-Darby canine kidney cells are injured by exposure to oxalate and to calcium oxalate crystals. Urological Research 1994 22 4 197 204 2-s2.0-0028072835 10.1007/BF00541892 (Pubitemid 24317071)
56. Khan S. R., Johnson J. M., Peck A. B., Cornelius J. G., Glenton P. A., Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. The Journal of Urology 2002 168 3 1173 1181 2-s2.0-0036716751
57. Tsujihata M., Miyake O., Yoshimura K., Kakimoto K. I., Takahara S., Okuyama A., Comparison of fibronectin content in urinary macromolecules between normal subjects and recurrent stone formers. European Urology 2001 40 4 458 462 2-s2.0-0035676774 10.1159/000049816 (Pubitemid 34036525)
58. Khan S. R., Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Experimental Nephrology 2004 98 2 e55 e60 2-s2.0-7544222033 10.1159/000080257
59. Khan S. R., Atmani F., Glenton P., Hou Z. C., Talham D. R., Khurshid M., Lipids and membranes in the organic matrix of urinary calcific crystals and stones. Calcified Tissue International 1996 59 5 357 365 2-s2.0-0029998529 10.1007/s002239900140 (Pubitemid 26367083)
60. Khan S. R., Glenton P. A., Backov R., Talham D. R., Presence of lipids in urine, crystals and stones: implications for the formation of kidney stones. Kidney International 2002 62 6 2062 2072 2-s2.0-0036434901 10.1046/j.1523-1755. 2002.00676.x (Pubitemid 35366160)
61. Khan S. R., Whalen P. O., Glenton P. A., Heterogeneous nucleation of calcium oxalate crystals in the presence of membrane vesicles. Journal of Crystal Growth 1993 134 3-4 211 218 2-s2.0-0027816789
62. Boyce W. H., Garvey F. K., The amount and nature of the organic matrix in urinary calculi: a review. The Journal of Urology 1956 76 3 213 227 2-s2.0-0001122577
63. Nishio S., Abe Y., Wakatsuki A., Matrix glycosaminoglycan in urinary stones. The Journal of Urology 1985 134 3 503 505 2-s2.0-0022386512 (Pubitemid 16236384)
64. Wessler E., The nature of the non-ultrafilterable glycosaminoglycans of normal human urine. The Biochemical Journal 1971 122 3 373 384 2-s2.0-0015039075
65. Yamaguchi S., Yoshioka T., Utsunomiya M., Koide T., Osafune M., Okuyama A., Sonoda T., Heparan sulfate in the stone matrix and its inhibitory effect on calcium oxalate crystallization. Urological Research 1993 21 3 187 192 2-s2.0-0027336973 (Pubitemid 23253436)
66. Suzuki K., Mayne K., Doyle I. R., Ryall R. L., Urinary glycosaminoglycans are selectively included into calcium oxalate crystals. Scanning Microscopy 1994 8 3 523 530 2-s2.0-0028650429
67. Iwata H., Kamei O., Abe Y., Nishio S., Wakatsuki A., Ochi K., Takeuchi M., The organic matrix of urinary uric acid crystals. The Journal of Urology 1988 139 3 607 610 2-s2.0-0023839682 (Pubitemid 18082910)
68. Shum D. K. Y., Gohel M. D. I., Separate effects of urinary chondroitin sulphate and heparan sulphate on the crystallization of urinary calcium oxalate: differences between stone formers and normal control subjects. Clinical Science 1993 85 1 33 39 2-s2.0-0027199113 (Pubitemid 23214374)
69. Samuell C. T., A study of glycosaminoglycan excretion in normal and stone-forming subjects using a modified cetylpyridinium chloride technique. Clinica Chimica Acta 1981 117 1 63 73 2-s2.0-0019856413 10.1016/0009-8981(81) 90010-3 (Pubitemid 12228487)
70. Ryall R. L., Glycosaminoglycans, proteins, and stone formation: adult themes and child's play. Pediatric Nephrology 1996 10 5 656 666 2-s2.0-0029777336 10.1007/s004670050185 (Pubitemid 26331787)
71. Erturk E., Kiernan M., Schoen S. R., Clinical association with urinary glycosaminoglycans and urolithiasis. Urology 2002 59 4 495 499 2-s2.0-0036127331 10.1016/S0090-4295(01)01649-1 (Pubitemid 34249869)
72. Dalsing M. C., Grosfeld G. L., Shiffler M. A., Superoxide dismutase: a cellular protective enzyme in bowel ischemia. The Journal of Surgical Research 1983 34 6 589 596 2-s2.0-0020593960 (Pubitemid 13067655)
73. Gokhale J. A., Glenton P. A., Khan S. R., Characterization of Tamm-Horsfall protein in a rat nephrolithiasis model. The Journal of Urology 2001 166 4 1492 1497 2-s2.0-0034821415 (Pubitemid 32862226)
74. Sikri K. L., Foster C. L., MacHugh N., Marshall R. D., Localization of Tamm-Horsfall glycoprotein in the human kidney using immune-fluorescence and immuno-electron microscopical techniques. Journal of Anatomy 1981 132 4 597 605 2-s2.0-0019455684 (Pubitemid 11117187)
75. Hunt J. S., McGiven A. R., Groufsky A., Lynn K. L., Taylor M. C., Affinity-purified antibodies of defined specificity for use in a solid-phase microplate radioimmunoassay of human Tamm-Horsfall glycoprotein in urine. The The Biochemical Journal 1994 227 3 957 963 2-s2.0-0021815850
76. Gokhale J. A., Glenton P. A., Khan S. R., Biochemical and quantitative analysis of Tamm Horsfall protein in rats. Urological Research 1997 25 5 347 354 2-s2.0-0030779541 10.1007/BF01294664 (Pubitemid 27461608)
77. Stevenson F. K., Cleave A. J., Kent P. W., The effect of ions on the viscometric and ultracentrifugal behaviour of Tamm-Horsfall glycoprotein. Biochimica et Biophysica Acta 1971 236 1 59 66 2-s2.0-0015242002
78. Serafini-Cessi F., Malagolini N., Cavallone D., Tamm-Horsfall glycoprotein: biology and clinical relevance. American Journal of Kidney Diseases 2003 42 4 658 676 2-s2.0-0141620216 10.1016/S0272-6386(03)00829-1 (Pubitemid 37187366)
79. Mo L., Huang H.-Y., Zhu X.-H., Shapiro E., Hasty D. L., Wu X.-R., Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney International 2004 66 3 1159 1166 2-s2.0-4344664015 10.1111/j.1523-1755.2004.00867.x (Pubitemid 39121023)
80. Kaneko K., Kobayashi R., Yasuda M., Izumi Y., Yamanobe T., Shimizu T., Comparison of matrix proteins in different types of urinary stone by proteomic analysis using liquid chromatography-tandem mass spectrometry. International Journal of Urology 2012 19 8 765 772 2-s2.0-84859635003 10.1111/j.1442-2042. 2012.03005.x
81. Robertson W. G., Scurr D. S., Bridge C. M., Factors influencing the crystallisation of calcium oxalate in urine-critique. Journal of Crystal Growth 1981 53 1 182 194 2-s2.0-33747570792
82. Fellstrom B., Danielson B. G., Ljunghall S., Wikstrom B., Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. Clinica Chimica Acta 1986 158 3 229 235 2-s2.0-0022477523 (Pubitemid 16025451)
83. Grover P. K., Marshall V. R., Ryall R. L., Tamm-Horsfall mucoprotein reduces promotion of calcium oxalate crystal aggregation induced by urate in human urine in vitro. Clinical Science 1994 87 2 137 142 2-s2.0-0028087728 (Pubitemid 24267080)
84. Rose G. A., Sulaiman S., Tamm-Horsfall mucoproteins promote calcium oxalate crystal formation in urine: quantitative studies. The Journal of Urology 1982 127 1 177 179 2-s2.0-0020030145 (Pubitemid 12172244)
85. Yoshioka T., Koide T., Utsunomiya M., Itatani H., Oka T., Sonoda T., Possible role of Tamm-Horsefall glycoprotein in calcium oxalate crystallisation. British Journal of Urology 1989 64 5 463 467 2-s2.0-0024815047 (Pubitemid 20018583)
86. Edyvane K. A., Hibberd C. M., Harnett R. M., Marshall V. R., Ryall R. L., Macromolecules inhibit calcium oxalate crystal growth and aggregation in whole human urine. Clinica Chimica Acta 1987 167 3 329 338 2-s2.0-0023281013 (Pubitemid 17142986)
87. Thornley C., Dawnay A., Cattell W. R., Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clinical Science 1985 68 5 529 535 2-s2.0-0021911580 (Pubitemid 15103432)
88. Marengo S. R., Chen D. H. C., Kaung H. L. C., Resnick M. I., Yang L., Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis. The Journal of Urology 2002 167 5 2192 2197 2-s2.0-0036223787 (Pubitemid 34309704)
89. Katsuma S., Shiojima S., Hirasawa A., Takagaki K., Kaminishi Y., Koba M., Hagidai Y., Murai M., Ohgi T., Yano J., Tsujimoto G., Global analysis of differentially expressed genes during progression of calcium oxalate nephrolithiasis. Biochemical and Biophysical Research Communications 2002 296 3 544 552 2-s2.0-18644377590 10.1016/S0006-291X(02)00840-9
90. Hess B., The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microscopy 1991 5 3 689 696 2-s2.0-0026218695
91. Hess B., Jaggi M., Zipperle L., Jaeger P., Reduced carbohydrate content of Tamm-Horsfall glycoprotein (THP) from severely recurrent Renal Calcium Stone Formers (RCSF). Journal of American Society of Nephrology 1995 6 949 952
92. Schnierle P., A simple diagnostic method for the differentiation of Tamm-Horsfall glycoproteins from healthy probands and those from recurrent calcium oxalate renal stone formers. Experientia 1995 51 11 1068 1072 2-s2.0-0028828229 10.1007/BF01946918
93. Nakagawa Y., Kaiser E. T., Coe F. L., Isolation and characterization of calcium oxalate crystal growth inhibitors from human urine. Biochemical and Biophysical Research Communications 1978 84 4 1038 1044 2-s2.0-0018080580 (Pubitemid 9053572)
94. Nakagawa Y., Margolis H. C., Yokoyama S., Kézdy F. J., Kaiser E. T., Coe F. L., Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. The Journal of Biological Chemistry 1981 256 8 3936 3944 2-s2.0-0019887930
95. Nakagawa Y., Abram V., Kezdy F. J., Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. The Journal of Biological Chemistry 1983 258 20 12594 12600 2-s2.0-0021031495 (Pubitemid 14231177)
96. Nakagawa Y., Parks J. H., Kézdy F. J., Coe F. L., Molecular abnormality of urinary glycoprotein crystal growth inhibitor in calcium nephrolithiasis. Transactions of the Association of American Physicians 1985 98 281 289 2-s2.0-0022179024
97. Coe F. L., Margolis H. C., Deutsch L. H., Strauss A. L., Urinary macromolecular crystal growth inhibitors in calcium nephrolithiasis. Mineral and Electrolyte Metabolism 1980 3 5 268 275 2-s2.0-0019202471 (Pubitemid 11227487)
98. Nakagawa Y., Ahmed M., Hall S. L., Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in γ -carboxyglutamic acid. The Journal of Clinical Investigation 1987 79 6 1782 1787 2-s2.0-0023228440 (Pubitemid 17117286)
99. 2+-binding sites in the kidney stone inhibitor glycoprotein nephrocalcin using vanadyl ions: different metal binding properties in strong and weak inhibitor proteins revealed by EPR and ENDOR. Biochemistry 1996 35 47 14703 14709 2-s2.0-0030473268
100. Nakagawa Y., Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. The Keio Journal of Medicine 1997 46 1 1 9 2-s2.0-0031087554 (Pubitemid 127470678)
101. Nakagawa Y., Netzer M., Coe F. L., Immunohistochemical localization of nephrocalcin (NC) to proximal tubule and thick ascending limb of Henle's loop (TALH) of human and mouse kidney: resolution of a conflict. Kidney International 1990 37 474
102. Nakagawa Y., Sirivongs D., Novy M. B., Netzer M. F., Michaels E., Vogelzang N. J., Coe F. L., Nephrocalcin: biosynthesis by human renal carcinoma cells in vitro and in vivo. Cancer Research 1992 52 6 1573 1579 2-s2.0-0026503195
103. Hess B., Nakagawa Y., Coe F. L., Walker V. R., Sutton R. A. L., Cameron E. C., Pak C. Y. C., Robertson W. G., Nephrocalcin isolated from human kidney stones is a defective calcium-oxalate-monohydrate crystal-aggregation inhibitor. Urolithiasis 1989 New York, NY, USA Plenum 137
104. Hochstrasser K., Reisinger P., Albrecht G., Wachter E., Schonberger O. L., Isolation of acid-resistant urinary trypsin inhibitors by high performance liquid chromatography and their characterization by N-terminal amino-acid sequence determination. Hoppe-Seyler's Zeitschrift fur Physiologische Chemie 1984 365 9 1123 1130 2-s2.0-0021144724 (Pubitemid 14014553)
105. Worcester E. M., Sebastian J. L., Hiatt J. G., Beshensky A. M., Sadowski J. A., The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcified Tissue International 1993 53 4 242 248 2-s2.0-0027301561 (Pubitemid 23275186)
106. Tang Y., Grover P. K., Moritz R. L., Simpson J., Ryall R. L., Is nephrocalcin related to the urinary derivative (bikunin) of inter- α -trypsin inhibitor? British Journal of Urology 1995 76 4 425 430 2-s2.0-0029135368
107. Atmani F., Lacour B., Drueke T., Daudon M., Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization. Urological Research 1993 21 1 61 66 2-s2.0-0027478824 10.1007/BF00295195 (Pubitemid 23058770)
108. Reinholt F. P., Hultenby K., Oldberg A., Heinegard D., Osteopontin-a possible anchor of osteoclasts to bone. Proceedings of the National Academy of Sciences of the United States of America 1990 87 12 4473 4475 2-s2.0-0025371582 10.1073/pnas.87.12.4473 (Pubitemid 20204123)
109. Prince C. W., Oosawa T., Butler W. T., Tomana M., Bhown A. S., Bhown M., Schrohenloher R. E., Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. The Journal of Biological Chemistry 1987 262 6 2900 2907 2-s2.0-0023664074
110. Oldberg A., Franzen A., Heinegard D., Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proceedings of the National Academy of Sciences of the United States of America 1986 83 23 8819 8823 2-s2.0-0001588341 (Pubitemid 17223492)
111. Addadi L., Weiner S., Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proceedings of the National Academy of Sciences of the United States of America 1985 82 12 4110 4114 2-s2.0-0021796043 (Pubitemid 15052838)
112. O'Brien E. R., Garvin M. R., Stewart D. K., Hinohara T., Simpson J. B., Schwartz S. M., Giachelli C. M., Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arteriosclerosis and Thrombosis 1994 14 10 1648 1656 2-s2.0-0028148368
113. Shiraga H., Min W., VanDusen W. J., Clayman M. D., Miner D., Terrell C. H., Sherbotie J. R., Foreman J. W., Przysiecki C., Neilson E. G., Hoyer J. R., Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proceedings of the National Academy of Sciences of the United States of America 1992 89 1 426 430 2-s2.0-0026571598
114. Kiefr M. C., Bauer D. M., Barr P. J., The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Research 1989 17 8 3306 2-s2.0-0024507060 (Pubitemid 19122248)
115. Franzen A., Heinegard D., Isolation and characterization of two sialoproteins present only in bone calcified matrix. The Biochemical Journal 1985 232 3 715 724 2-s2.0-0022354869 (Pubitemid 16207308)
116. Worcester E. M., Urinary calcium oxalate crystal growth inhibitors. Journal of the American Society of Nephrology 1994 5 1 S46 S53 2-s2.0-0028543970 (Pubitemid 24986609)
117. Basavaraj D. R., Biyani C. S., Browning A. J., Cartledge J. J., The role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium containing renal stones. EAU-EBU Update Series 2007 5 3 126 136 2-s2.0-34247209738 10.1016/j.eeus.2007.03.002 (Pubitemid 46621786)
118. Fraij B. M., Separation and identification of urinary proteins and stone-matrix proteins by mini-slab sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Clinical Chemistry 1989 35 4 658 662 2-s2.0-0024515985 (Pubitemid 19111088)
119. Iida S., Peck A. B., Byer K. J., Khan S. R., Expression of bikunin mRNA in renal epithelial cells after oxalate exposure. The Journal of Urology 1999 162 4 1480 1486 2-s2.0-0032822502 10.1016/S0022-5347(05)68344-9 (Pubitemid 29428622)
120. Merchant M. L., Cummins T. D., Wilkey D. W., Salyer S. A., Powell D. W., Klein J. B., Lederer E. D., Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. American Journal of Physiology 2008 295 4 F1254 F1258 2-s2.0-57049167619 10.1152/ajprenal.00134.2008
121. Canales B. K., Anderson L., Higgins L., Ensrud-Bowlin K., Roberts K. P., Wu B., Kim I. W., Monga M., Proteome of human calcium kidney stones. Urology 2010 76 4 1017.e13 1017.e20 2-s2.0-77957752486 10.1016/j.urology.2010.05.005
122. Worcester E. M., Beshensky A. M., Osteopontin inhibits nucleation of calcium oxalate crystals. Annals of the New York Academy of Sciences 1995 760 375 377 2-s2.0-0029120723 10.1111/j.1749-6632.1995.tb44661.x
123. Nishio S., Hatanaka M., Takeda H., Aoki K., Iseda T., Iwata H., Yokoyama M., Calcium phosphate crystal-associated proteins: α 2-HS-glycoprotein, prothrombin F1, and osteopontin. Molecular Urology 2000 4 4 383 390 2-s2.0-0033636384
124. Christensen B., Petersen T. E., Sørensen E. S., Post-translational modification and proteolytic processing of urinary osteopontin. The Biochemical Journal 2008 411 1 53 61 2-s2.0-41649098345 10.1042/BJ20071021 (Pubitemid 351482346)
125. Boyce W. H., King J., Fielden M., Total Non-Dialyzable Solids (TNDS) in human urine XIII. Immunological detection of a component peculiar to renal calculous matrix and to urine of calculous patients. The Journal of Clinical Investigation 1962 41 5 1180 1189 10.1172/JCI104571
126. Dussol B., Geider S., Lilova A., Leonetti F., Duput P., Daudon M., Berland Y., Dagorn J.-C., Verdier J.-M., Analysis of the soluble organic matrix of five morphologically different kidney stones. Evidence for a specific role of albumin in the constitution of the stone protein matrix. Urological Research 1995 23 1 45 51 2-s2.0-0028920338 10.1007/BF00298850
127. Cerini C., Geider S., Dussol B., Hennequin C., Daudon M., Veesler S., Nitsche S., Boistelle R., Berthézène P., Dupuy P., Vazi A., Berland Y., Dagorn J.-C., Verdier J.-M., Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation. Kidney International 1999 55 5 1776 1786 2-s2.0-0032920292 10.1046/j.1523-1755.1999. 00426.x (Pubitemid 29197965)
128. Suzuki K., Moriyama M., Nakajima C., Kawamura K., Miyazawa K., Tsugawa R., Kikuchi N., Nagata K., Isolation and partial characterization of crystal matrix protein as a potent inhibitor of calcium oxalate crystal aggregation: evidence of activation peptide of human prothrombin. Urological Research 1994 22 1 45 50 2-s2.0-0028331654 (Pubitemid 24149220)
129. Ryall R. L., Grover P. K., Stapleton A. M. F., Barrell D. K., Tang Y., Moritz R. L., Simpson R. J., The urinary FI activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clinical Science 1995 89 5 533 541 2-s2.0-0028874829
130. Grover P. K., Ryall R. L., Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. European Journal of Biochemistry 1999 263 1 50 56 2-s2.0-0033168864 10.1046/j.1432-1327.1999.00448.x (Pubitemid 29313837)
131. Grover P. K., Ryall R. L., Effect of prothrombin and its activation fragments on calcium oxalate crystal growth and aggregation in undiluted human urine in vitro: relationship between protein structure and inhibitory activity. Clinical Science 2002 102 4 425 434 2-s2.0-0036203574 10.1042/CS20010223 (Pubitemid 34275795)
132. Tardivel S., Médétognon J., Randoux C., Kébédé M., Drüeke T., Daudon M., Hennequin C., Lacour B., Alpha-1-microglobulin: inhibitory effect on calcium oxalate crystallization in vitro and decreased urinary concentration in calcium oxalate stone formers. Urological Research 1999 27 4 243 249 2-s2.0-0344069545 10.1007/s002400050117 (Pubitemid 29431739)
133. Pillay S. N., Asplin J. R., Coe F. L., Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. American Journal of Physiology 1998 275 2 part 2 F255 F261 2-s2.0-0031847270
134. Mushtaq S., Siddiqui A. A., Naqvi Z. A., Rattani A., Talati J., Palmberg C., Shafqat J., Identification of myeloperoxidase, α -defensin and calgranulin in calcium oxalate renal stones. Clinica Chimica Acta 2007 384 1-2 41 47 2-s2.0-34547838283 10.1016/j.cca.2007.05.015 (Pubitemid 47247407)
135. Bennett J., Dretler S. P., Selengut J., Orme-Johnson W. H., Identification of the calcium-binding protein calgranulin in the matrix of struvite stones. Journal of Endourology 1994 8 2 95 98 2-s2.0-0028023236 (Pubitemid 24305777)
136. Atmani F., Mizon J., Khan S. R., Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter- α -inhibitor. European Journal of Biochemistry 1996 236 3 984 990 2-s2.0-0029876777 (Pubitemid 26122172)
137. Steinbuch M., The inter-alpha-trypsin inhibitor. Methods in Enzymology 1976 45 760 772 2-s2.0-0017218149 10.1016/S0076-6879(76)45069-3
138. Atmani F., Lacour B., Jungers P., Drüeke T., Daudon M., Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers. Urological Research 1994 22 4 257 260 2-s2.0-0027996384 10.1007/BF00541903 (Pubitemid 24317082)
139. Médétognon-Benissan J., Tardivel S., Hennequin C., Daudon M., Drüeke T., Lacour B., Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers. Urological Research 1999 27 1 69 75 2-s2.0-2542508504 10.1007/s002400050091 (Pubitemid 29145093)
140. Atmani F., Khan S. R., Role of urinary bikunin in the inhibition of calcium oxalate crystallization. Journal of the American Society of Nephrology 1999 10 14 S385 S388 2-s2.0-0032706470 (Pubitemid 29498586)
141. Ebisuno S., Nishihata M., Inagaki T., Umehara M., Kohjimoto Y., Bikunin prevents adhesion of calcium oxalate crystal to renal tubular cells in human urine. Journal of the American Society of Nephrology 1999 10 14 S436 S440
142. Verdier J. M., Dussol B., Casanova P., Daudon M., Dupuy P., Berthezene P., Boistelle R., Berland Y., Dagorn J.-C., Renal lithostathine, a new inhibitor of urinary stones formation. Nephrologie 1993 14 6 261 264 2-s2.0-0027892959 (Pubitemid 24084682)
143. Geider S., Dussol B., Nitsche S., Veesler S., Berthézène P., Dupuy P., Astier J. P., Boistelle R., Berland Y., Dagorn J. C., Verdier J. M., Calcium carbonate crystals promote calcium oxalate crystallization by heterogeneous or epitaxial nucleation: possible involvement in the control of urinary lithogenesis. Calcified Tissue International 1996 59 1 33 37 2-s2.0-8944256870 10.1007/s002239900082 (Pubitemid 26235007)
144. Grover P. K., Kim D. S., Ryall R. L., The effect of seed crystals of hydroxyapatite and brushite on the crystallization of calcium oxalate in undiluted human urine in vitro: implications for urinary stone pathogenesis. Molecular Medicine 2002 8 4 200 209 2-s2.0-0036042611 (Pubitemid 35013751)
145. Priyadarshini P., Singh S. K., Tandon C., Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix. Clinica Chimica Acta 2009 408 1-2 34 38 2-s2.0-69849095121 10.1016/j.cca.2009.06.041
146. Priyadarshini P., Naik P. K., Sengupta D., Singh S. K., Tandon C. D., Mode of interaction of calcium oxalate crystal with human phosphate cytidylyltransferase 1: a novel inhibitor purified from human renal stone matrix. Journal of Biomedical Science and Engineering 2011 4 9 591 598 2-s2.0-69849095121 10.4236/jbise.2011.49075
147. Sorokina E. A., Wesson J. A., Kleinman J. G., An acidic peptide sequence of nucleolin-related protein can mediate the attachment of calcium oxalate to renal tubule cells. Journal of the American Society of Nephrology 2004 15 8 2057 2065 2-s2.0-3543088021 10.1097/01.ASN.0000133024.83256.C8 (Pubitemid 39031345)
148. Aggarwal K. P., Tandon S., Naik P. K., Singh S. K., Tandon C. D., Novel antilithiatic cationic proteins from human calcium oxalate renal stone matrix identified by MALDI-TOF-MS endowed with cytoprotective potential: an insight into molecular mechanism of urolithiasis. Clinica Chimica Acta 2012 415 181 190
149. Kumar V., Yu S., Farell G., Toback F. G., Lieske J. C., Renal epithelial cells constitutively produce a protein that blocks adhesion of crystals to their surface. American Journal of Physiology 2004 287 3 F373 F383 2-s2.0-4143135176 10.1152/ajprenal.00418.2003 (Pubitemid 39095950)
150. Verkoelen C. F., Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan? Journal of the American Society of Nephrology 2006 17 6 1673 1687 2-s2.0-33646906175 10.1681/ASN.2006010088 (Pubitemid 43794670)
151. Verhulst A., Asselman M., Persy V. P., Schepers M. S. J., Helbert M. F., Verkoelen C. F., De Broe M. E., Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding-into a nonadherent epithelium. Journal of the American Society of Nephrology 2003 14 1 107 115 2-s2.0-12244260735 10.1097/01.ASN.0000038686.17715.42 (Pubitemid 36026302)
152. Asselman M., Verhulst A., De Broe M. E., Verkoelen C. F., Calcium oxalate crystal adherence to Hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. Journal of the American Society of Nephrology 2003 14 12 3155 3166 2-s2.0-1542361303 10.1097/01.ASN.0000099380.18995.F7 (Pubitemid 38312570)
153. Chutipongtanate S., Nakagawa Y., Sritippayawan S., Pittayamateekul J., Parichatikanond P., Westley B. R., May F. E. B., Malasit P., Thongboonkerd V., Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor. Journal of Clinical Investigation 2005 115 12 3613 3622 2-s2.0-31044450826 10.1172/JCI25342 (Pubitemid 43121850)
154. Thongboonkerd V., Chutipongtanate S., Semangoen T., Malasit P., Urinary trefoil factor 1 is a novel potent inhibitor of calcium oxalate crystal growth and aggregation. The Journal of Urology 2008 179 4 1615 1619 2-s2.0-40849151863 10.1016/j.juro.2007.11.041
155. Kim M. J., Tam F. W. K., Urinary monocyte chemoattractant protein-1 in renal disease. Clinica Chimica Acta 2011 412 23-24 2022 2030 2-s2.0-80053637659 10.1016/j.cca.2011.07.023
156. Umekawa T., Chegini N., Khan S. R., Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells. Kidney International 2002 61 1 105 112 2-s2.0-0036147229 10.1046/j.1523-1755.2002. 00106.x (Pubitemid 34075136)
157. Kumar V., Farell G., Deganello S., Lieske J. C., Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals. Journal of the American Society of Nephrology 2003 14 2 289 297 2-s2.0-0037305125 10.1097/01.ASN.0000046030.24938.0A (Pubitemid 36150851)
158. Proudfoot D., Shanahan C. M., Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology 2006 11 5 455 461 2-s2.0-33749132161 10.1111/j.1440-1797.2006.00660.x (Pubitemid 44470096)
159. Gao B., Yasui T., Itoh Y., Tozawa K., Hayashi Y., Kohri K., A polymorphism of matrix Gla protein gene is associated with kidney stones. The Journal of Urology 2007 177 6 2361 2365 2-s2.0-34248182932 10.1016/j.juro.2007. 01.118 (Pubitemid 46726390)
160. Cancela M. L., Hu B., Price P. A., Effect of cell density and growth factors on matrix GLA protein expression by normal rat kidney cells. Journal of Cellular Physiology 1997 171 2 125 134 10.1002/(SICI)1097-4652(199705)171: 2<125::AID-JCP2>3.0.CO;2-Q (Pubitemid 27205053)
161. Lu X., Gao B., Yasui T., Li Y., Liu T., Mao X., Kohri K., Xiao C., Matrix Gla protein is involved in crystal formation in kidney of hyperoxaluric rats. Kidney and Blood Pressure Research 2013 37 1 15 23 10.1159/000343396
162. Gao B., Yasui T., Lu X., Zhou H., Liu J., Liu P., Okada A., Xiao C., Kohri K., Matrix Gla protein expression in NRK-52E cells exposed to oxalate and calcium oxalate monohydrate crystals. Urologia Internationalis 2010 85 2 237 241 2-s2.0-77957265713 10.1159/000314947
163. Latha P., Kalaiselvi P., Varalakshmi P., Rameshkumar G., Characterization of histone (H1B) oxalate binding protein in experimental urolithiasis and bioinformatics approach to study its oxalate interaction. Biochemical and Biophysical Research Communications 2006 345 1 345 354 2-s2.0-33745798676 10.1016/j.bbrc.2006.04.086 (Pubitemid 44269285)
164. Brown L. P., Berse B., Van De Water L., Papadopoulos-Sergiou A., Perruzzi C. A., Manseau E. J., Dvorak H. F., Senger D. R., Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Molecular Biology of the Cell 1992 3 10 1169 1180 2-s2.0-0027096666 (Pubitemid 23088966)
165. Hoyer J. R., Uropontin in urinary calcium stone formation. Mineral and Electrolyte Metabolism 1995 760 6 375 377 2-s2.0-0028934388
166. Wesson J. A., Worcester E. M., Wiessner J. H., Mandel N. S., Kleinman J. G., Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney International 1998 53 4 952 957 2-s2.0-0031959536 10.1111/j.1523-1755.1998.00839.x (Pubitemid 28155669)
167. Hedgepeth R. C., Yang L., Resnick M. I., Marengo S. R., Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals. American Journal of Kidney Diseases 2001 37 1 104 112 2-s2.0-0035170037 (Pubitemid 32055025)
168. Yamate T., Tsuji H., Amasaki N., Iguchi M., Kurita T., Kohri K., Analysis of osteopontin DNA in patients with urolithiasis. Urological Research 2000 28 3 159 166 2-s2.0-0033920344 (Pubitemid 30435675)
169. Stapleton A. M. F., Simpson R. J., Ryall R. L., Crystal matrix protein is related to human prothrombin. Biochemical and Biophysical Research Communications 1993 195 3 1199 1203 2-s2.0-0027492933 10.1006/bbrc.1993.2171 (Pubitemid 23290281)
170. Stapleton A. M. F., Ryall R. L., Blood coagulation proteins and urolithiasis are linked: crystal matrix protein is the F1 activation peptide of human prothrombin. British Journal of Urology 1995 75 6 712 719 2-s2.0-0029064896
171. Suzuki K., Tanaka T., Miyazawa K., Nakajima C., Moriyama M., Suga K., Murai M., Yano J., Gene expression of prothrombin in human and rat kidneys: basic and clinical approach. Journal of the American Society of Nephrology 1999 10 14 S408 S411 2-s2.0-0032754107 (Pubitemid 29498591)
172. Stapleton A. M. F., Ryall R. L., Crystal matrix protein-getting blood out of a stone. Mineral and Electrolyte Metabolism 1995 20 6 399 409 2-s2.0-0028927585
173. Stapleton A. M. F., Seymour A. E., Brennan J. S., Doyle I. R., Marshall V. R., Ryall R. L., Immunohistochemical distribution and quantification of crystal matrix protein. Kidney International 1993 44 4 817 824 2-s2.0-0027364791 (Pubitemid 23290523)
174. Stapleton A. M. F., Timme T. L., Ryall R. L., Gene expression of prothrombin in the human kidney and its potential relevance to kidney stone disease. British Journal of Urology 1998 81 5 666 672 2-s2.0-0031819214 10.1046/j.1464-410X.1998.00620.x (Pubitemid 28316627)
175. Salier J.-P., Inter- α -trypsin inhibitor: emergence of a family within the Kunitz-type protease inhibitor superfamily. Trends in Biochemical Sciences 1990 15 11 435 439 2-s2.0-0025086005 (Pubitemid 20376583)
176. Franck C., Pedersen J. Z., Trypsin-inhibitory activities of acid-stable fragments of the inter-alpha-trypsin inhibitor in inflammatory and uraemic conditions. Scandinavian Journal of Clinical and Laboratory Investigation 1983 43 2 151 155 2-s2.0-0020531962 (Pubitemid 13118797)
177. Chawla R. K., Rausch D. J., Miller F. W., Vogler W. R., Lawson D. H., Abnormal profile of serum proteinase inhibitors in cancer patients. Cancer Research 1984 44 6 2718 2723 2-s2.0-0021154817 (Pubitemid 14108364)
178. Toki N., Sumi H., Urinary trypsin inhibitor and urokinase activities in renal diseases. Acta Haematologica 1982 67 2 109 113 2-s2.0-0020024558 (Pubitemid 12168654)
179. Bauer J., Reich Z., Uber die antitryptische. Wirkung des Harns. Medizinische Klinik 1909 46 1744 1747
180. Atmani F., Lacour B., Strecker G., Parvy P., Drueke T., Daudon M., Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro. Biochemical and Biophysical Research Communications 1993 191 3 1158 1165 2-s2.0-0027185586 10.1006/bbrc.1993.1338 (Pubitemid 23231611)
181. Hochstrasser K., Bretzel G., Feuth H., Hilla W., Lempart K., The inter α trypsin inhibitor as precursor of the acid stable proteinase inhibitors in human serum and urine. Hoppe-Seyler's Zeitschrift fur Physiologische Chemie 1976 357 2 153 162 2-s2.0-0017249217
182. Enghild J. J., Thogersen I. B., Pizzo S. V., Salvesen G., Analysis of inter- α -trypsin inhibitor and a novel trypsin inhibitor, pre- α -trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. The Journal of Biological Chemistry 1989 264 27 15975 15981 2-s2.0-0024459170 (Pubitemid 19238354)
183. Janssen U., Thomas G., Glant T., Phillips A., Expression of inter- α -trypsin inhibitor and tumor necrosis factor-stimulated gene 6 in renal proximal tubular epithelial cells. Kidney International 2001 60 1 126 136 2-s2.0-0034958841 10.1046/j.1523-1755.2001.00779.x (Pubitemid 32587547)
184. Iida S., Peck A. B., Johnson-Tardieu J., Moriyama M., Glenton P. A., Byer K. J., Khan S. R., Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. Journal of the American Society of Nephrology 1999 10 5 986 996 2-s2.0-0032931730 (Pubitemid 29203085)
185. Suzuki S., Kobayashi H., Kageyama S., Shibata K., Fujie M., Terao T., Excretion of bikunin and its fragments in the urine of patients with renal stones. The Journal of Urology 2001 166 1 268 274 2-s2.0-0034967442 (Pubitemid 32565410)
186. Dean C., Kanellos J., Pham H., Gomes M., Oates A., Grover P., Ryall R., Effects of inter- α -inhibitor and several of its derivatives on calcium oxalate crystallization in vitro. Clinical Science 2000 98 4 471 480 2-s2.0-0034032714 (Pubitemid 30197863)
187. Kobayashi H., Shibata K., Fujie M., Sugino D., Terao T., Identification of structural domains in inter- α -trypsin inhibitor involved in calcium oxalate crystallization. Kidney International 1998 53 6 1727 1735 2-s2.0-0031749823 10.1046/j.1523-1755.1998.00940.x (Pubitemid 28243757)
188. Okuyama M., Yamaguchi S., Yachiku S., Identification of bikunin isolated from human urine inhibits calcium oxalate crystal growth and its localization in the kidneys. International Journal of Urology 2003 10 10 530 535 2-s2.0-0242720927 10.1046/j.1442-2042.2003.00677.x (Pubitemid 37378461)
189. Atmani F., Opalko F. J., Khan S. R., Association of urinary macromolecules with calcium oxalate crystals induced in vitro in normal human and rat urine. Urological Research 1996 24 1 45 50 2-s2.0-0029875479 10.1007/BF00296733 (Pubitemid 26078579)
190. Zimmer D., Cornwall E., Landar A., Song W., The S100 protein family: history, function, and expression. Brain Research Bulletin 1995 37 4 417 429 2-s2.0-0028928357 10.1016/0361-9230(95)00040-2
191. Naito Y., Ohtawara Y., Kageyama S., Nakano M., Ichiyama A., Fujita M., Suzuki K., Kawabe K., Kino I., Morphological analysis of renal cell culture models of calcium phosphate stone formation. Urological Research 1997 25 1 59 65 2-s2.0-0030946411 10.1007/BF00941907 (Pubitemid 27141805)
192. 3 crystal growth. European Journal of Clinical Investigation 1992 22 7 469 474 2-s2.0-0026653565
193. Atmani F., Glenton P. A., Khan S. R., Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urological Research 1998 26 3 201 207 2-s2.0-0031779154 10.1007/s002400050047 (Pubitemid 28305386)
194. Hess B., Meinhardt U., Zipperle L., Giovanoli R., Jaeger P., Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. Urological Research 1995 23 4 231 238 2-s2.0-0029156180 10.1007/BF00393304
195. Ebrahimpour A., Perez L., Nancollas G. H., Induced crystal growth of calcium oxalate monohydrate at hydroxapatite surfaces. The influence of human serum albumin, citrate, and magnesium. Langmuir 1991 7 3 577 583 2-s2.0-0026121786
196. Ribieras S., Tomasetto C., Rio M. C., The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochimica et Biophysica Acta 1998 1378 1 F61 F77 2-s2.0-0032547383 10.1016/S0304-419X(98)00016-X (Pubitemid 28381126)
197. Lee J. Y., Spicer A. P., Hyaluronan: a multifunctional, megaDalton, stealth molecule. Current Opinion in Cell Biology 2000 12 5 581 586 2-s2.0-0033812683 10.1016/S0955-0674(00)00135-6
198. Toole B. P., Hyaluronan in morphogenesis. Journal of Internal Medicine 1997 242 1 35 40 2-s2.0-0030766519 (Pubitemid 27323863)
199. Toole B. P., Developmental role of hyaluronate. Connective Tissue Research 1982 10 1 93 100 2-s2.0-0020326415 (Pubitemid 12018703)
200. Sibalic V., Fan X., Loffing J., Wüthrich R. P., Upregulated renal tubular CD44, hyaluronan, and osteopontin in kdkd mice with interstitial nephritis. Nephrology Dialysis Transplantation 1997 12 7 1344 1353 2-s2.0-0030797233 10.1093/ndt/12.7.1344 (Pubitemid 27353022)
201. Göransson V., Johnsson C., Jacobson A., Heldin P., Hällgren R., Hansell P., Renal hyalurona accumulation and hyaluronan synthase expression after ischaemia-reperfusion injury in the rat. Nephrology Dialysis Transplantation 2004 19 4 823 830 2-s2.0-1842523228 10.1093/ndt/gfh003 (Pubitemid 38455652)
202. Feusi E., Sun L., Sibalic A., Beck-Schimmer B., Oertli B., Wüthrich R. P., Enhanced hyaluronan synthesis in the MRL-Fas(lpr) kidney: role of cytokines. Nephron 1999 83 1 66 73 2-s2.0-0032841959 10.1159/000045475 (Pubitemid 29417649)
203. Wells A., Larsson E., Hanas E., Laurent T., Hallgren R., Tufveson G., Increased hyaluronan in acutely rejecting human kidney grafts. Transplantation 1993 55 6 1346 1349 2-s2.0-0027319826 (Pubitemid 23183249)
204. Wüthrich R. P., The proinflammatory role of hyaluronan-CD44 interactions in renal injury. Nephrology Dialysis Transplantation 1999 14 11 2554 2556 2-s2.0-0033280661 (Pubitemid 32208356)
205. Jones S. G., Ito T., Phillips A. O., Regulation of proximal tubular epithelial cell CD44-mediated binding and internalisation of hyaluronan. The International Journal of Biochemistry and Cell Biology 2003 35 9 1361 1377 2-s2.0-0038044648 10.1016/S1357-2725(03)00040-2 (Pubitemid 36703174)
206. Gerke V., Moss S. E., Annexins: from structure to function. Physiological Reviews 2002 82 2 331 371 2-s2.0-0036083696 (Pubitemid 34654456)
207. Ma A. S. P., Ozers L. J., Annexins I and II show differences in subcellular localization and differentiation related changes in human epidermal keratinocytes. Archives of Dermatological Research 1996 288 10 596 603 2-s2.0-0029789037 10.1007/s004030050109 (Pubitemid 26335335)
208. Hajjar K. A., Guevara C. A., Lev E., Dowling K., Chacko J., Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. Essential role of endonexin repeat 2. The Journal of Biological Chemistry 1996 271 35 21652 21659 2-s2.0-0029788890 10.1074/jbc.271.35.21652 (Pubitemid 26293036)
209. Eberhard D. A., Vandenberg S. R., Annexins I and II bind to lipid A: a possible role in the inhibition of endotoxins. The Biochemical Journal 1998 330 1 part 1 67 72 2-s2.0-0032519492 (Pubitemid 28075723)
210. Raynor C. M., Wright J. F., Waisman D. M., Pryzdial E. L., Annexin II enhances cytomegalovirus binding and fusion to phospholipid membranes. Biochemistry 1999 38 16 5089 5095 2-s2.0-0033586748 10.1021/bi982095b (Pubitemid 29196356)
211. Baran D. T., Quail J. M., Ray R., Leszyk J., Honeyman T., Annexin II is the membrane receptor that mediates the rapid actions of 1 α25- dihydroxyvitamin D3. Journal of Cellular Biochemistry 2000 78 1 34 46 2-s2.0-0034043855 (Pubitemid 30346381)
212. Ma K., Simantov R., Zhang J. C., Silverstein R., Hajjar K. A., McCrae K. R., High affinity binding of β 2-glycoprotein I to human endothelial cells is mediated by annexin II. The Journal of Biological Chemistry 2000 275 20 15541 15548 2-s2.0-0034685886 10.1074/jbc.275.20.15541 (Pubitemid 30337288)
213. Hajjar K. S., Mauri L., Jacovina A. T., Zhong F., Mirza U. A., Padovan J. C., Chait B. T., Tissue plasminogen activator binding to the annexin II tail domain: direct modulation by homocysteine. The Journal of Biological Chemistry 1998 273 16 9987 9993 2-s2.0-0032540276 10.1074/jbc.273.16.9987 (Pubitemid 28183100)
214. Yan L., Zucker S., Toole B. P., Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thrombosis and Haemostasis 2005 93 2 199 204 2-s2.0-13844296556 10.1160/TH04-08-0536 (Pubitemid 40253722)
215. Weber G. F., Ashkar S., Glimcher M. J., Cantor H., Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996 271 5248 509 512 2-s2.0-0030064334 (Pubitemid 26044470)
216. Yamazaki M., Nakajima F., Ogasawara A., Moriya H., Majeska R. J., Einhorn T. A., Spatial and temporal distribution of CD44 and osteopontin in fracture callus. Journal of Bone and Joint Surgery B 1999 81 3 508 515 2-s2.0-0033029158 10.1302/0301-620X.81B3.9398 (Pubitemid 29245911)
217. Verkoelen C. F., Van der Boom B. G., Romijn J. C., Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney International 2000 58 3 1045 1054 2-s2.0-0033863330 10.1046/j.1523-1755.2000.00262.x
218. Fraser J. D., Price P. A., Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the γ -carboxylase. The Journal of Biological Chemistry 1988 263 23 11033 11036 2-s2.0-0023739850
219. Luo G., Ducy P., McKee M. D., Pinero G. J., Loyer E., Behringer R. R., Karsenty G., Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protien. Nature 1997 386 6620 78 81 2-s2.0-0030947025 10.1038/386078a0 (Pubitemid 27130923)
220. Murshed M., Schinke T., McKee M. D., Karsenty G., Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. Journal of Cell Biology 2004 165 5 625 630 2-s2.0-2942631661 10.1083/jcb.200402046 (Pubitemid 38765764)
221. Gu L., Tseng S. C., Rollins B. J., Monocyte chemoattractant protein-1. Chemical Immunology 1999 72 7 29 2-s2.0-0032773634 (Pubitemid 29403341)
222. Wagner W., Roderburg C., Wein F., Diehlmann A., Frankhauser M., Schubert R., Eckstein V., Ho A. D., Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells 2007 25 10 2638 2647 2-s2.0-35348826635 10.1634/stemcells.2007-0280 (Pubitemid 47582757)
223. Hyduk S. J., Chan J. R., Duffy S. T., Chen M., Peterson M. D., Waddell T. K., Digby G. C., Szaszi K., Kapus A., Cybulsky M. I., Phospholipase C, calcium, and calmodulin are critical for α 4 β 1 integrin affinity up-regulation and monocyte arrest triggered by chemoattractants. Blood 2007 109 1 176 184 2-s2.0-33846027057 10.1182/blood-2006-01-029199 (Pubitemid 46053059)
224. Duffield J. S., Macrophages and immunologic inflammation of the kidney. Seminars in Nephrology 2010 30 3 234 254 2-s2.0-77953881058 10.1016/j. semnephrol.2010.03.003
225. Yadav A., Saini V., Arora S., MCP-1: chemoattractant with a role beyond immunity: a review. Clinica Chimica Acta 2010 411 21-22 1570 1579 2-s2.0-79955784400 10.1016/j.cca.2010.07.006
226. Pathak P., Singh S. K., Tandon C., Effect of biomolecules from human renal matrix of calcium oxalate monohydrate (CaOx) stones on in vitro calcium phosphate crystallization. International Brazilian Journal of Urology 2010 36 5 621 628 2-s2.0-78650185897 10.1590/S1677-55382010000500013
227. Moghadam M. F., Tandon C., Aggarwal S., Singla S. K., Singh S. K., Sharma S. K., Varshney G. C., Jethi R. K., Concentration of a potent calcium oxalate monohydrate crystal growth inhibitor in the urine of normal persons and kidney stone patients by ELISA-based assay system employing monoclonal antibodies. Journal of Cellular Biochemistry 2003 90 6 1261 1275 2-s2.0-0345305852 10.1002/jcb.10671 (Pubitemid 37485060)
228. Aggarwal S., Tandon C., Forouzandeh M., Singla S. K., Kiran R., Jethi R. K., Role of a protein inhibitor isolated from human renal stone matrix in urolithiasis. Indian Journal of Biochemistry and Biophysics 2005 42 2 113 117 2-s2.0-28244452022 (Pubitemid 41704742)
229. Aggarwal K. P., Tandon S., Singh S. K., Tandon C. D., 2D map of proteins from human renal stone matrix and evaluation of their effect on oxalate induced renal tubular epithelial cell injury. International Brazilian Journal of Urology 2013 39 1 128 136